title: [Effect of the location of previous atherosclerotic disease on prognosis in diabetic patients. The Barbanza Diabetes Study].
abstract: OBJECTIVE
  To assess the effect of different forms of atherosclerotic disease on prognosis in diabetic patients.
  
  
  METHODS
  This multicenter prospective cohort study involved 1423 consecutive patients with diabetes mellitus who were recruited by 31 primary care physicians. The patients' characteristics were recorded and they were followed up for 45 +/- 10 months.
  
  
  RESULTS
  The mean age of the patients (50% male) was 66 years, 64% had hypertension, 70% had dyslipidemia, and 26% had had a previous cardiovascular event. By the end of follow-up, 81 (6.2%) had died, 40 (3%) of whom due to cardiovascular causes, and 393 (30%) had been hospitalized, 179 (14%) of whom for cardiovascular disease. Multivariate analysis identified the following factors as independent predictors of mortality: age (hazard ratio [HR]=1.08; 95% confidence interval [CI],1.05-1.11), previous cardiovascular disease (HR=2.15; 95% CI, 1.12-4.14) and diuretic treatment (HR=3.40; 95% CI, 1.76-6.56), while the prescription of an angiotensin-converting enzyme inhibitor or an angiotensin-receptor antagonist had a protective effect (HR=0.48; 95% CI, 0.25-0.93). Compared with diabetics without a previous cardiovascular event, the risk of a cardiovascular event during follow-up was greater in those with a history of either ischemic heart disease (HR=2.48; 95% CI, 1.51-4.07), cerebrovascular disease (HR=2.51; 95% CI, 1.28-4.92), or peripheral vascular disease (HR=1.46; 95% CI, 0.81-2.60).
  
  
  CONCLUSIONS
  The increase in the risk of a cardiovascular event was similar in diabetics with ischemic heart disease and those with cerebrovascular disease. In both cases, the risk was more than double that in patients without a history of cardiovascular disease.
authors.affiliation: Servicio de Cardiología, Hospital Clínico Universitario de Santiago, A Coruña, Spain. jose.ramon.gonzalez.juanatey@sergas.es
authors.forename: José R
authors.initials: JR
authors.lastname: González-Juanatey
authors.forename: Lilian
authors.initials: L
authors.lastname: Grigorian-Shamagian
authors.forename: María A
authors.initials: MA
authors.lastname: Juiz-Crespo
authors.forename: Manuel
authors.initials: M
authors.lastname: Sánchez-Loureiro
authors.forename: Esperanza
authors.initials: E
authors.lastname: Rodríguez-Moldes
authors.forename: Jaime
authors.initials: J
authors.lastname: Dopico-Pita
authors.forename: Genaro
authors.initials: G
authors.lastname: Gutiérrez-Fernández
authors.forename: Jorge
authors.initials: J
authors.lastname: Torres-Colomer
authors.forename: Rubén
authors.initials: R
authors.lastname: Blanco-Rodríguez
authors.forename: Fernando
authors.initials: F
authors.lastname: Otero-Raviña
mesh_terms: D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D000959:Antihypertensive Agents; D050197:Atherosclerosis / Q000453:epidemiology / Q000473:pathology*; D003920:Diabetes Mellitus / Q000453:epidemiology / Q000401:mortality / Q000473:pathology*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D011446:Prospective Studies; D013030:Spain / Q000453:epidemiology; D055815:Young Adult
chemical_list: D000959:Antihypertensive Agents